Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 19/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 19/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 19/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 17/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 16/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24313387 | 0.77 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL24312699 | 0.77 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL24449467 | 0.74 | KMT2A (0.52) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL19229732 | 0.74 | PIK3CD (0.44) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL15730403 | 0.72 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18532202 | 0.71 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL23338433 | 0.71 | HSD17B10 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL24449814 | 0.69 | POLB (0.45) | — | |
| SCHEMBL24312690 | 0.69 | DPP4 (0.35) | DPP4 | |
| SCHEMBL31655263 | 0.69 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |